Technical Analysis for GLYC - GlycoMimetics, Inc.

Grade Last Price % Change Price Change
grade F 4.41 -2.65% -0.12
GLYC closed down 2.65 percent on Friday, September 20, 2019, on approximately normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical GLYC trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -2.65%
NR7 Range Contraction -2.65%
NR7-2 Range Contraction -2.65%
Bearish Engulfing Bearish -2.65%
Upper Bollinger Band Walk Strength -2.65%
Weak + Overbought Other -2.65%

Older signals for GLYC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Biotechnology Health Pharmaceutical Industry Diseases Chemotherapy Drug Discovery Clinical Trial Acute Myeloid Leukemia Design Of Experiments Product Testing Pseudomonas Sickle Cell Disease Hematologic Cancers Nursing Research
Is GLYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.72
52 Week Low 2.64
Average Volume 1,130,324
200-Day Moving Average 10.0804
50-Day Moving Average 5.7762
20-Day Moving Average 3.8835
10-Day Moving Average 4.441
Average True Range 0.3808
ADX 30.63
+DI 21.1642
-DI 22.1678
Chandelier Exit (Long, 3 ATRs ) 3.7576
Chandelier Exit (Short, 3 ATRs ) 4.2424
Upper Bollinger Band 5.0763
Lower Bollinger Band 2.6907
Percent B (%b) 0.72
BandWidth 61.429123
MACD Line -0.1574
MACD Signal Line -0.4152
MACD Histogram 0.2578
Fundamentals Value
Market Cap 144.31 Million
Num Shares 32.7 Million
EPS -1.34
Price-to-Earnings (P/E) Ratio -3.29
Price-to-Sales 18873.21
Price-to-Book 3.02
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.90
Resistance 3 (R3) 4.94 4.82 4.82
Resistance 2 (R2) 4.82 4.70 4.80 4.79
Resistance 1 (R1) 4.62 4.62 4.56 4.57 4.76
Pivot Point 4.50 4.50 4.47 4.47 4.50
Support 1 (S1) 4.29 4.37 4.23 4.25 4.06
Support 2 (S2) 4.17 4.29 4.15 4.03
Support 3 (S3) 3.97 4.17 4.00
Support 4 (S4) 3.92